302 related articles for article (PubMed ID: 28118650)
1. Pembrolizumab (Keytruda) for first-line treatment of metastatic NSCLC.
Med Lett Drugs Ther; 2017 Jan; 59(1513):22-23. PubMed ID: 28118650
[No Abstract] [Full Text] [Related]
2. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
3. Immuno-oncology drugs jostle for first-line setting.
Mullard A
Nat Rev Drug Discov; 2016 Nov; 15(11):738. PubMed ID: 27807351
[No Abstract] [Full Text] [Related]
4. Pembrolizumab Outperforms Docetaxel for NSCLC.
Leslie M
Cancer Discov; 2016 Mar; 6(3):223. PubMed ID: 26811324
[No Abstract] [Full Text] [Related]
5. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
Dang TO; Ogunniyi A; Barbee MS; Drilon A
Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948
[TBL] [Abstract][Full Text] [Related]
6. More Benefits for Checkpoint Inhibitors in NSCLC.
Cancer Discov; 2015 Dec; 5(12):OF2. PubMed ID: 26511141
[TBL] [Abstract][Full Text] [Related]
7. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab for the treatment of non-small cell lung cancer.
Muller M; Schouten RD; De Gooijer CJ; Baas P
Expert Rev Anticancer Ther; 2017 May; 17(5):399-409. PubMed ID: 28338376
[TBL] [Abstract][Full Text] [Related]
9. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
Peters S; Kerr KM; Stahel R
Cancer Treat Rev; 2018 Jan; 62():39-49. PubMed ID: 29156447
[TBL] [Abstract][Full Text] [Related]
10. Clinical Trials of PD-1 and PD-L1 inhibitors in NSCLC.
Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):14-6. PubMed ID: 24852398
[No Abstract] [Full Text] [Related]
11. Pembrolizumab Shows Promise for NSCLC.
Cancer Discov; 2015 Jun; 5(6):572. PubMed ID: 25895920
[TBL] [Abstract][Full Text] [Related]
12. Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.
Remon J; Pardo N; Martinez-Martí A; Cedrés S; Navarro A; Martinez de Castro AM; Felip E
Lung Cancer; 2017 Apr; 106():70-75. PubMed ID: 28285697
[TBL] [Abstract][Full Text] [Related]
13. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
Langer CJ
Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable.
Prasad V; Kaestner V
Semin Oncol; 2017 Apr; 44(2):132-135. PubMed ID: 28923211
[TBL] [Abstract][Full Text] [Related]
15. First-Line Immune Therapy-Implications for Pathologists.
Miller RA; Cagle PT; Bernicker EH
Arch Pathol Lab Med; 2016 Aug; 140(8):739-40. PubMed ID: 27472228
[No Abstract] [Full Text] [Related]
16. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
Ayers M; Lunceford J; Nebozhyn M; Murphy E; Loboda A; Kaufman DR; Albright A; Cheng JD; Kang SP; Shankaran V; Piha-Paul SA; Yearley J; Seiwert TY; Ribas A; McClanahan TK
J Clin Invest; 2017 Aug; 127(8):2930-2940. PubMed ID: 28650338
[TBL] [Abstract][Full Text] [Related]
17. Improved outcomes with pembrolizumab treatment in two cases of double cancer including non-small-cell lung cancer.
Yamada H; Hida N; Satoh H; Yamagishi T; Hiroshima Y; Yoshii S; Saito T; Hizawa N
Anticancer Drugs; 2019 Jan; 30(1):105-109. PubMed ID: 30074503
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of efficacy and safety of different pembrolizumab dose/schedules in treatment of non-small-cell lung cancer and melanoma: a systematic review.
Abdel-Rahman O
Immunotherapy; 2016 Dec; 8(12):1383-1391. PubMed ID: 27892744
[TBL] [Abstract][Full Text] [Related]
19. Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient.
Pellegrino B; Musolino A; Tiseo M
Ann Oncol; 2017 Jun; 28(6):1405-1406. PubMed ID: 28383638
[No Abstract] [Full Text] [Related]
20. A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor.
Chang AL; Kim J; Luciano R; Sullivan-Chang L; Colevas AD
JAMA Dermatol; 2016 Jan; 152(1):106-8. PubMed ID: 26422398
[No Abstract] [Full Text] [Related]
[Next] [New Search]